2007 in cancer

FDA · US: 35 records / 22 drugsEMA · EU: 8 records / 8 drugsHealth Canada · CA: 5 records / 3 drugs

• Oct 29, 2007Nilotinib FDA · US original application approved Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 PositivePediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.openfda
• Oct 29, 2007Nilotinib FDA · US original application approved Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 PositiveAdult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.openfda
• Oct 11, 2007Topotecan FDA · US original application approved Lung Small Cell CarcinomaHYCAMTIN ® capsules are indicated for the treatment of relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response and who are…openfda
• May 30, 2007Temsirolimus FDA · US original application approved Renal Cell CarcinomaTORISEL is indicated for the treatment of advanced renal cell carcinoma. TORISEL ® is a kinase inhibitor indicated for the treatment of advanced renal cell…openfda
• May 3, 2007Histrelin FDA · US original application approved Conventional OsteosarcomaSUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP…openfda
• Apr 16, 2007Zoledronic Acid FDA · US original application approved Paget DiseaseTreatment of Paget’s disease of bone in men and womenopenfda
• Mar 13, 2007Lapatinib FDA · US original application approved Malignant Breast NeoplasmTYKERB ® is indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human…openfda
• Oct 29, 2007Nilotinib FDA · US original application approved cancer not stated in this recordAdult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in…openfda
• Jul 26, 2007Tretinoin FDA · US original application approved cancer not stated in this recordAtralin Gel is indicated for topical treatment of acne vulgaris. Atralin Gel is a retinoid indicated for topical treatment of acne vulgaris. ( 1 )openfda
• Apr 16, 2007Zoledronic Acid FDA · US original application approved cancer not stated in this recordTreatment and prevention of postmenopausal osteoporosis • Treatment to increase bone mass in men with osteoporosis • Treatment and prevention of…openfda
• Dec 3, 2007Panitumumab EMA · EU centralised approved Malignant Colorectal NeoplasmVectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): in first-line in combination with Folfox or…ema
• Nov 19, 2007Nilotinib EMA · EU centralised approved Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 PositiveTasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia…ema
• Dec 14, 2007Thyrotropin Alfa FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-12-14 (see label)openfda
• Dec 3, 2007Mitoxantrone Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as MITOXANTRONE INJECTION (DIN 02286300) under ATC L01DB07 MITOXANTRONE. Indications are not published in the Drug Product Database — see…health-canada-dpd
• Nov 19, 2007Temsirolimus EMA · EU centralised approved cancer not stated in this recordRenal-cell carcinoma Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of…ema
• Nov 16, 2007Sorafenib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-16 (see label)openfda
• Nov 16, 2007Sorafenib Tosylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-16 (see label)openfda
• Nov 16, 2007Sorafenib Tosylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-16 (see label)openfda
• Nov 16, 2007Sorafenib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-16 (see label)openfda
• Nov 16, 2007Sorafenib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-16 (see label)openfda
• Nov 16, 2007Sorafenib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-16 (see label)openfda
• Nov 16, 2007Sorafenib Tosylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-16 (see label)openfda
• Nov 16, 2007Sorafenib Tosylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-16 (see label)openfda
• Nov 8, 2007Dasatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-08 (see label)openfda
• Nov 8, 2007Dasatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-11-08 (see label)openfda
• Oct 10, 2007Bortezomib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-10-10 (see label)openfda
• Oct 2, 2007Cetuximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-10-02 (see label)openfda
• Sep 28, 2007Docetaxel FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-09-28 (see label)openfda
• Sep 19, 2007Alemtuzumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-09-19 (see label)openfda
• Sep 17, 2007Trabectedin EMA · EU centralised approved cancer not stated in this recordYondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to…ema
• Sep 13, 2007Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-09-13 (see label)openfda
• Sep 13, 2007Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-09-13 (see label)openfda
• Sep 7, 20075-Aminolevulinic Acid EMA · EU centralised approved cancer not stated in this recordGliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (World Health Organization grade III and IV).ema
• Aug 22, 2007Nelarabine EMA · EU centralised approved cancer not stated in this recordNelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease…ema
• Jun 29, 2007Hydroxycarbamide EMA · EU centralised approved cancer not stated in this recordSiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering…ema
• Jun 14, 2007Lenalidomide EMA · EU centralised approved cancer not stated in this recordMultiple myeloma Revlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone…ema
• May 17, 2007Doxorubicin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-05-17 (see label)openfda
• May 9, 2007Vinorelbine Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as VINORELBINE TARTRATE FOR INJECTION (DIN 02271214) under ATC L01CA04 VINORELBINE. Indications are not published in the Drug Product…health-canada-dpd
• Apr 13, 2007Dasatinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as SPRYCEL (DIN 02293145) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Apr 13, 2007Dasatinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as SPRYCEL (DIN 02293129) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Apr 13, 2007Dasatinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as SPRYCEL (DIN 02293137) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Feb 15, 2007Paclitaxel FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-02-15 (see label)openfda
• Feb 2, 2007Sunitinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-02-02 (see label)openfda
• Feb 2, 2007Sunitinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-02-02 (see label)openfda
• Feb 2, 2007Sunitinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-02-02 (see label)openfda
• Jan 30, 2007Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-01-30 (see label)openfda
• Jan 30, 2007Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-01-30 (see label)openfda
• Jan 26, 2007Azacitidine FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2007-01-26 (see label)openfda

RegulatoryAll 2007 records with filters →

Studies

3,415

Interventional

2,914

Phase III

402

Industry-led

898

With posted results

1,142

Countries with sites

90

Published source: clinicaltrials · first_posted_date as posted